Press Releases

For Immediate Release
Date: July 18, 2011
Fiona Macrae, Global Marketing Manager, Communications, Microbiology Products, Thermo Fisher Scientific
Phone: +44 (0) 1256 694318
E-mail: fiona.macrae@thermofisher.com

Thermo Fisher Scientific Acquires TREK Diagnostic Systems
Range of Manual and Automated Equipment and Consumables Support Productivity Advances in Microbiology Labs

BASINGSTOKE, England. (July 18, 2011) – Thermo Fisher Scientific, the world leader in serving science, today announced that it has acquired TREK Diagnostic Systems, a global provider of microbiology solutions, including blood culture, microorganism identification and antibiotic susceptibility testing products.

The addition of VersaTREK® platforms to its microbiology portfolio allows Thermo Fisher to offer automated systems for blood culture and the detection of mycobacteria for the first time. VersaTREK complements the company’s manual blood culture systems, to provide the most comprehensive choice of tests and culture media for use in the diagnosis of sepsis and tuberculosis.

TREK’s other major brand, Sensititre, extends Thermo Fisher’s range of manual susceptibility testing and identification products that provide microbiologists with a range of tools to determine the resistance status of a microorganism.

“This acquisition is an important step in our strategy to bring a greater choice of workflow solutions to microbiologists worldwide,” said Andrew Carr, President, Microbiology, Thermo Fisher Scientific. “TREK is an ideal complement to our existing capabilities, allowing us to offer comprehensive solutions to aid in the diagnosis of sepsis. We can now provide easier access to technology used in the setting of global standards in antimicrobial susceptibility testing, for targeted antibiotic therapy and promotion of good antibiotic stewardship. And we will now offer a fully automated alternative for mycobacterial detection and resistance, crucial to the diagnosis of tuberculosis. Additionally, TREK has a significant product development pipeline that will be enhanced by the expertise and resources of Thermo Fisher Scientific.”

Trek products now join the industry-leading Thermo Scientific portfolio; a portfolio that is relied on for its quality, accuracy, reliability and innovation and that also encompasses the Oxoid and Remel brands which, like Trek, have a strong heritage in microbiology.

For more information please contact fiona.macrae@thermofisher.com or visit www.trekds.com.

Notes for Editors

About TREK Diagnostic Systems
Headquartered near Cleveland, Ohio, with offices also in Sun Prairie, WI, USA and East Grinstead, W. Sussex, UK. the company had full year revenue in 2010 of $34 million and has 160 employees. It serves pharmaceutical and clinical laboratory markets, where strong growth has been experienced in the USA.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.